Concepedia

Michael Gulrajani

MG

10

Publications

1.1K

Citations

10

H-Index

2015

Active since

Affiliations

The Ohio State University(Current)

AstraZeneca (United States)

National Heart Lung and Blood Institute

Michael Gulrajani is an author at The Ohio State University specializing in oncology, medicine, and immunology.

Top concepts

Publications per year

2015–2020

10

Publications

10

Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile

Tjeerd Barf, Todd Covey, Raquel Izumi et al. · Journal of Pharmacology and Experimental Therapeutics · 2017 · 357 citations · Full text

Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results

John C. Byrd, William G. Wierda, Anna Schuh et al. · Blood · 2019 · 172 citations · Full text

The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia

Sarah E. M. Herman, Arnau Montraveta, Carsten Utoft Niemann et al. · Clinical Cancer Research · 2016 · 157 citations · Full text

Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib

Clare Sun, Pia Nierman, Ellen K. Kendall et al. · Blood · 2020 · 101 citations · Full text

Potency and Selectivity of BTK Inhibitors in Clinical Development for B-Cell Malignancies

Allard Kaptein, Gerjan de Bruin, Maaike Emmelot-van Hoek et al. · Blood · 2018 · 92 citations

Rows per page

1–5 of 10